ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > COVID serology test competitor approval

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Nov 25, 2020 4:13pm

100 Views

Post# 31972400

RE:RE:RE:COVID serology test competitor approval

Yes, I heard the same thing on CNN yesterday by William Haseltine, a former Harvard Medical professor. He said:

"Don't think it protects infection so that you may be infected, but you don't get so sick. So what they really are majoring in is not the prevention of infection; they're majoring in the prevention of symptoms."

This may apply to all 3 vaccines. Moderna, Pfizer, AstraZeneca

G1945V

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (June 28, 2024)